Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07500220 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Name: Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC — clinical trial record (NCT07500220)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUET-HCC

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-03-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Liver Cancer

1,505 trials monitored

See 60 trials at risk

open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma. The design intentionally uses GPC3 as the primary target anchor because GPC3 is the dominant HCC cell-therapy antigen in current clinical development, while adding B7-H3 to reduce antigen escape and to broaden coverage across tumor and tumor-microenvironment compartments. The study first evaluates safety and dose-limiting toxicities, then expands at the recommended phase 2 dose.

Trial Details

NCT Number	NCT07500220
Lead Sponsor	Beijing Biotech
Conditions	Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Enrollment	30 participants
Start Date	2026-03-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-03-30